Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A method for the treatment of a disease or disorder by modulating the activity of at least one neurotrophin and/or a pro-neurotrophin in an organism in need thereof, said method comprising administering to said organism an effective amount of an agent capable of

   (i)   binding to a receptor of the Vps10p-domain receptor family and/or

   (ii) interfering with binding between a receptor of the Vps10p-domain receptor family and a neurotrophin and/or proneurotrophin

   and/or

   (iii) modulating the expression of a receptor of the Vps10p-domain receptor family.

2. (previously presented) The method according to claim 1, wherein said method is for the treatment of a neurological disease or disorder.

3. (previously presented) The method according to claim 1, wherein the modulation is a decrease of the activity.

4. (previously presented) The method according to claim 1, wherein the modulation is an increase of the activity.

5. (previously presented) The method according to claim 1, wherein the neurotrophin is selected from the group consisting of: neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5).

6. (cancelled)

7. (previously presented) The method according to claim 1, wherein the pro-neurotrophin is selected from the group consisting of: pro-NGF, pro-BDNF, pro-NT-3 or pro-NT-4/5.

8-9. (cancelled)

10. (previously presented) The method according to claim 1, wherein the organism is a human being.

11. (previously presented) The method according to claim 1, wherein the receptor is selected from the group consisting of: SorLA, Sortilin, SorCS1, SorCS-2, and SorCS-3.

12. (cancelled)

13. (previously presented) The method according to claim 1, wherein the agent is selected from the group consisting of: proteins, peptides, polypeptides, antibodies, antisense RNA, antisense-DNA or organic molecules, and SiRNA.

14. (previously presented) The method according to claim 1, wherein the agent is capable of inhibiting binding of said neurotrophin or said pro-neurotrophin to the receptor.

15. (previously presented) The method according to claim 1, wherein the agent is capable of binding to an extracellular part of the receptor.

16. (previously presented) The method according to claim 1, wherein the agent is an antibody directed against, an extracellular part of the receptor, an intracellular part of the receptor, or a transmembrane part of the receptor.

17. (previously presented) The method according to claim 16, wherein the agent is an antibody directed against a peptide comprising a sequence comprising amino acid residues 612-740 of SEQ ID NO:1.

18. (previously presented) The method according to claim 15, wherein the agent is a peptide comprising a sequence comprising amino acids 24-77 of SEQ ID NO:1, or a variant thereof, said peptide being capable of binding to the receptor.

19. (previously presented) The method according to claim 18, wherein the variant comprises or consists of amino acid residues 29-81 (propart from SorLa) of SEQ ID NO:2.

20. (previously presented) The method according to claim 18, wherein the peptide is capable of binding to the receptor

and comprises one or more of the sequences in the group consisting of: SEQ ID NO: 6, amino acid residues 19-121 (propart for NGF); SEQ ID NO 7, amino acid residues 19-127 (propart for BDNF); SEQ ID NO: 8, amino acid residues 17-124 (propart for neurotrophin-3 (NT-3); SEQ ID NO: 9, amino acid residues 25-80 (propart for neurotrophin-4 (NT-4); and a fragments or variants thereof.

21. (previously presented) The method according to claim 1, wherein the agent is a peptide comprising a Sortilin receptor-binding sequence of proNGF.

22. (previously presented) The method according to claim 20, wherein the agent is a peptide capable of binding to the receptor that comprises the sequence SEQ ID NO: 6, amino acid residues 19-121 (the sequence from the pro-part of NGF) or a variant thereof.

23. (previously presented) The method according to claim 21, wherein the agent is a peptide consisting of the following sequence: SEQ ID NO: 6, amino acid residues 19-121 (propeptide of proNGF).

24. (previously presented) The method according to claim 1, wherein the agent is a peptide capable of binding to the receptor that comprises the sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or a fragment or a variant thereof.

25. (previously presented) The method according to claim 1, wherein the agent is a peptide comprising an NGF variant or a Sortilin-receptor binding fragment of said NGF variant.

26. (cancelled)

27. (previously presented) The method according to claim 1, wherein the agent is SEQ ID NO: 2 amino acid residues 47-66.

28. (previously presented) The method according to claim 1, wherein the agent is SEQ ID NO: 13

29. (previously presented) The method according to claim 1, wherein the agent is a fragment or variant of RAP (receptor-associated protein - SEQ ID NO. 12).

30. (previously presented) The method according to claim 29, wherein said agent is from 20 to 60 amino acids long and comprises the preferred domain amino acid positions 219-323 of receptor-associated protein.

31. (previously presented) The method according to claim 1, wherein the agent is a peptide comprising a sequence comprising amino acids 34-77 of SEQ ID NO: 1 ,or a variant thereof, said peptide being capable of binding to the receptor.

32. (previously presented) The method according to claim 1, wherein the agent is a peptide comprising a sequence comprising amino acids 50-70 of SEQ ID NO: 1 or a variant thereof, said peptide being capable of binding to the receptor.

33. (previously presented) The method according to claim 1, wherein the disease or disorder is selected from the group consisting of: inflammatory pain, diseases or disorders of pancreas, kidney disorders, lung disorders, cardiovascular disorders, various types of tumours, psychiatric disorders and neuronal disorders.

34. (previously presented) The method according to claim 1, wherein the disease or disorder is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, Huntington's chorea, stroke, ALS, peripheral neuropathies, necrosis or loss of neurons, nerve damage to trauma, kidney dysfunction, injury, and the toxic effects of chemotherapeutics used to treat cancer and AIDS, aberrant sprouting in epilepsy, schizophrenia, pancreas or lung injury and/or dysfunction, and injury and/or dysfunction of the central and/or peripheral nervous systems.

35. (previously presented) The method according to claim 1, wherein the disease or disorder is selected from the group consisting of: peripheral neuropathy, distal sensorimotor neuropathy, or autonomic neuropathies, such as reduced motility of the gastrointestinal tract or atony of the urinary

bladder, post-polio syndrome or AIDS-associated neuropathy; hereditary neuropathies, such as Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinemia, Tangier disease, Krabbe's disease, Metachromatic leukodystrophy, Fabry's disease, and Dejerine-Sottas syndrome, depression, mania and Down's syndrome.

36. (previously presented) The method according to claim 1, wherein said agent is for the development, maintenance, or regeneration of neurons in an individual.

37. (previously presented) The method according to claim 1, wherein said agent is for the treatment of nerve damage by any cause in the group consisting of: trauma, bums, kidney dysfunction or injury, pancreatic dysfunction or injury, lung dysfunction or injury, injury to fatty tissue, and the toxic effects of chemotherapeutics used to treat cancer and AIDS.

38-39. (cancelled)

40. (previously presented) The method according to claim 1, wherein said treatment is for human neurodegenerative disorders.

41. (previously presented) The method according to claim 1, wherein said treatment is for a motoneuron disorders.

42. (previously presented) The method according to claim 1, wherein the disease or disorder is a neuropathy.

43. (withdrawn) The method according to claim 1, wherein the disease or disorder is depression or mania.

44. (withdrawn) The method according to claim 1, wherein said agent is used as a cognitive enhancer.

45. (previously presented) The method according to claim 1, wherein the agent is administered in an amount of from 1 μg/kg to about 100 mg/kg per day.

46-69. (cancelled)

70. (withdrawn) A pharmaceutical composition comprising an antibody directed against a peptide comprising a sequence comprising amino acids 612-740 of SEQ ID NO:1, and a pharmaceutically acceptable carrier.

6

71.(cancelled)